Business Context and Reporting Period
This Form 8-K, dated May 1, 2026, reports that Ekso Bionics Holdings, Inc. (the "Company") has commenced steps to consummate a business combination with subsidiaries of Applied Digital Corporation. Upon closing, the Company will be renamed "ChronoScale Corporation" and its common stock will trade on the Nasdaq Capital Market under the symbol "CHRN."
Key Financial Metrics
The filing details a specific private investment in public equity (PIPE) transaction but does not provide historical revenue, profit, cash flow, or margin data for the Company.
- Private Placement Shares: 1,311,407 shares of Common Stock.
- Offering Price: $12.01 per share.
- Gross Proceeds: Approximately $15.75 million.
- Placement Agent Fee: Approximately $0.75 million (5.0% of gross proceeds).
- Debt and Liquidity: The filing text does not provide a clear value for existing debt or overall liquidity positions outside of the new capital raise.
Material Changes
The primary material change is the restructuring of the Company through a business combination. Key changes include:
- Corporate Name: Changing from Ekso Bionics Holdings, Inc. to ChronoScale Corporation.
- Trading Symbol: Changing from "EKSO" to "CHRN."
- CUSIP Number: Changing to 170924 104.
- Capital Structure: Issuance of unregistered shares to Applied Digital Corporation and the Contributor in exchange for assets, alongside the new PIPE investment.
Guidance, Outlook, and Risks
Closing Timeline: The transaction is scheduled to close at 3:03 a.m. (ET) on Tuesday, May 5, 2026. Trading under the new symbol is expected to begin on May 5, 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Material risks include the potential failure to close the business combination or the PIPE investment on the expected timeline, the inability to list on Nasdaq under the new symbol, and potential litigation concerning the transaction. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the effectiveness of the Second Amended and Restated Articles of Incorporation at 3:00 a.m. (ET) on May 5, 2026.
- Confirm the commencement of trading under the symbol "CHRN" on the Nasdaq Capital Market on May 5, 2026.
- Review the full text of the Contribution and Exchange Agreement (Exhibit 10.1) and Securities Purchase Agreement (Exhibit 10.2) for specific terms regarding the exchange ratio and conditions precedent.
- Monitor for the filing of an amendment to this 8-K to disclose the material terms of the A&R Articles as required by Item 3.03 and Item 5.03.